IceCure Reports Strong Q1 Revenue Growth, 46% Increase in US Customer Accounts Post-FDA Clearance

summarizeSummary

IceCure Medical reported a 26% increase in global revenue for Q1 2026, driven by an 84% surge in North American sales and a 46% rise in active U.S. customer accounts following recent FDA clearance for its ProSense® system.

check_boxKey Events · Earnings and Guidance · ICCM

• Strong Revenue Growth

  Global revenue increased 26% to $911,000 in Q1 2026, with North American sales up 84% and U.S. sales up 31% year-over-year, driven by increased adoption of ProSense®.

• Significant Customer Adoption

  Active U.S. customer accounts for ProSense® increased by 46% to 19 as of March 31, 2026, following FDA clearance for early-stage breast cancer.

• Improved Gross Profit

  Gross profit rose 35% to $295,000, with gross margin improving to 32% in Q1 2026 compared to 30% in the prior year period.

• Cash Position Update

  Cash and cash equivalents totaled $8.115 million as of March 31, 2026, reflecting the impact of $3.537 million in net proceeds from share and warrant issuance during the quarter, following a prior 'going concern' warning.

auto_awesomeAnalysis · ICCM · Industrial Applications And Services

This earnings report shows significant commercial momentum for IceCure's ProSense® system, particularly in the U.S. market, following its recent FDA clearance for breast cancer treatment. The substantial increase in active customer accounts and revenue growth are critical for a company that recently disclosed a 'going concern' warning and raised capital. While the company continues to operate at a net loss, these adoption metrics indicate progress towards sustainable operations and validate its commercial strategy, especially as the stock trades near its 52-week low.